drugset
drugset / Trial / NCT03207347

A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)

NCT03207347 ↗

Phase 2 Completed 37 enrolled University of Florida GlaxoSmithKline · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This open-label, non-randomized study will investigate the use of niraparib in patients with tumors known to have mutations in BAP1 and other select DNA damage response pathway genes.

Timeline

Start
2018-08-13
Primary completion
2022-08-30
Completion
2022-08-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Niraparib Small molecule 300 mg Oral

Indications

cholangiocarcinoma mesothelioma renal cell carcinoma uveal melanoma